Biological effects of acetomycin. I. Activity against tumor cells in vitro and in vivo.
The antibiotic acetomycin was active in vitro against HCT-8 human colon adenocarcinoma cells (IC50, 1.5 microgram/ml) and L1210 murine leukemia cells (IC50, 2.2 micrograms/ml). Acetomycin also had marked activity in the human tumor stem cell assay, with a 33% overall response rate (less than or equal to 30% survival) against 49 primary tumors. However, acetomycin was inactive in four in vivo tumor assay systems (L1210 and P388 leukemias, B16 melanoma and the MX-1 mammary xenograft system). This lack of in vivo activity may result from metabolic inactivation of acetomycin.
D000230:Adenocarcinoma; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms; D005663:Furans / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D014410:Tumor Stem Cell Assay
D000903:Antibiotics, Antineoplastic; D005663:Furans; C047794:acetomycin